Related Experiment Video
Updated: Jun 12, 2026
Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
Published on: December 29, 2023
Efficacy and Safety of Paclitaxel Plus Ramucirumab as Second-Line Therapy in Advanced Gastric Cancer: A
Varun Goel1, Arpit Jain1, Nivedita Patnaik2
1Department of Medical Oncology, Rajiv Gandhi Cancer Hospital, New Delhi, India.
Background:
Advanced gastric cancer (AGC) has limited treatment options beyond first-line therapy. The combination of paclitaxel and ramucirumab is an approved second-line regimen. This study evaluates the real-world efficacy and safety of this combination in Indian patients.
Aim:
To assess the effectiveness and tolerability of paclitaxel plus ramucirumab in advanced gastric/gastroesophageal junction adenocarcinoma in a real-world setting.
Materials And Methods:
This retro-prospective study included 85 patients with AGC treated between January 2020 and December 2024 at a tertiary cancer centre in North India. Patients received paclitaxel 80 mg/m² on days 1, 8, and 15, and ramucirumab 8 mg/kg on days 1 and 15 of a 28-day cycle. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.
Results:
The median age was 58 years; 71% were male. ECOG PS 0-1 was present in 70%. Prior gastrectomy was reported in 36%. Median PFS was 5.1 months, and OS was 9.3 months. ORR was 27%, and DCR was 66%. Common grade 3/4 adverse events included neutropenia (19%), neuropathy (13%), and hypertension (9%).
Conclusion:
Paclitaxel plus ramucirumab is effective and well-tolerated as second-line treatment in Indian AGC patients. Outcomes mirror global data and support its continued use in resource-limited settings.
